Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DS, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Pang A, Harajli D, Sakr WA, Sheng S.

Cancer Res. 2017 Feb 15;77(4):886-896. doi: 10.1158/0008-5472.CAN-16-2219. Epub 2016 Dec 6.

2.

Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.

Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, Heath E, Kim HR, Bonfil RD.

J Transl Med. 2016 Mar 15;14:72. doi: 10.1186/s12967-016-0829-5.

3.

The mouse prostate: a basic anatomical and histological guideline.

Oliveira DS, Dzinic S, Bonfil AI, Saliganan AD, Sheng S, Bonfil RD.

Bosn J Basic Med Sci. 2016 Feb 10;16(1):8-13. doi: 10.17305/bjbms.2016.917. Review.

4.

Maspin expression in prostate tumor elicits host anti-tumor immunity.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S.

Oncotarget. 2014 Nov 30;5(22):11225-36.

5.

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD.

Int J Cancer. 2015 Jan 1;136(1):11-20. doi: 10.1002/ijc.28948. Epub 2014 May 20.

6.

Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.

Yin S, Xu L, Bonfil RD, Banerjee S, Sarkar FH, Sethi S, Reddy KB.

Mol Cancer Ther. 2013 Apr;12(4):491-8. doi: 10.1158/1535-7163.MCT-12-1090. Epub 2013 Feb 27.

7.

Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S.

Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170.

8.

Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.

Fridman R, Benton G, Aranoutova I, Kleinman HK, Bonfil RD.

Nat Protoc. 2012 May 17;7(6):1138-44. doi: 10.1038/nprot.2012.053.

PMID:
22596226
9.

Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Najy AJ, Jung YS, Won JJ, Conley-LaComb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.

Prostate. 2012 Sep 1;72(12):1328-38. doi: 10.1002/pros.22481. Epub 2011 Dec 27.

10.

PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.

Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28.

11.

A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.

Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-LaComb MK, Wiesner C, Saliganan A, Cher ML, Kim HR.

Oncogene. 2012 Oct 18;31(42):4527-35. doi: 10.1038/onc.2011.573. Epub 2011 Dec 12.

12.

Circulating tumor cells: finding the needle in the haystack.

Zhe X, Cher ML, Bonfil RD.

Am J Cancer Res. 2011;1(6):740-51. Epub 2011 Jun 1.

13.

Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.

Mahalingam CD, Datta T, Patil RV, Kreider J, Bonfil RD, Kirkwood KL, Goldstein SA, Abou-Samra AB, Datta NS.

J Endocrinol. 2011 Nov;211(2):145-56. doi: 10.1530/JOE-11-0144. Epub 2011 Aug 18.

14.

Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML.

Cancer Res. 2010 Jul 1;70(13):5558-66. doi: 10.1158/0008-5472.CAN-09-4416. Epub 2010 Jun 15.

15.

Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.

Mainetti LE, Rozados VR, Rossa A, Bonfil RD, Scharovsky OG.

J Cancer Res Clin Oncol. 2011 Jan;137(1):151-63. doi: 10.1007/s00432-010-0869-9. Epub 2010 Mar 27.

PMID:
20349084
16.

Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?

Bonfil RD, Fridman R, Mobashery S, Cher ML.

Curr Oncol. 2008 Aug;15(4):188-92. No abstract available.

17.

C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.

Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thüroff JW, Vessella RL, Cher ML, Bonfil RD.

Neoplasia. 2008 Sep;10(9):996-1003.

18.

Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML.

Neoplasia. 2008 May;10(5):439-49.

19.

Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models.

Rozados VR, Hinrichsen LI, Binda MM, Gervasoni SI, Matar P, Bonfil RD, Scharovsky OG.

Oncol Rep. 2008 May;19(5):1205-11.

PMID:
18425377
20.

The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP.

Cho JA, Osenkowski P, Zhao H, Kim S, Toth M, Cole K, Aboukameel A, Saliganan A, Schuger L, Bonfil RD, Fridman R.

J Biol Chem. 2008 Jun 20;283(25):17391-405. doi: 10.1074/jbc.M708943200. Epub 2008 Apr 15.

21.

CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML.

Mol Cancer Res. 2008 Mar;6(3):446-57. doi: 10.1158/1541-7786.MCR-07-0117.

22.

Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.

Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, Cher ML.

Int J Cancer. 2008 Jun 1;122(11):2482-90. doi: 10.1002/ijc.23431.

23.

Paradoxical antiproliferative effect by a murine mammary tumor-derived epithelial cell line.

Gurzov EN, Nabha SM, Yamamoto H, Meng H, Scharovsky OG, Bonfil RD.

BMC Cancer. 2007 Oct 1;7:184.

24.

Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.

Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML.

Urol Oncol. 2007 Sep-Oct;25(5):407-11. Review.

PMID:
17826661
25.

Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.

Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, Cher ML.

Am J Pathol. 2007 Jun;170(6):2100-11.

26.

Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.

Wiesner C, Bonfil RD, Dong Z, Yamamoto H, Nabha SM, Meng H, Saliganan A, Sabbota A, Cher ML.

Urology. 2007 Apr;69(4):795-9.

PMID:
17445684
27.

Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.

Nabha SM, Bonfil RD, Yamamoto HA, Belizi A, Wiesner C, Dong Z, Cher ML.

Clin Exp Metastasis. 2006;23(7-8):335-44. Epub 2006 Nov 30.

PMID:
17136575
28.

Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.

Yamamoto H, Bonfil RD, Wiesner C, Nabha S, Dong Z, Meng H, Saliganan A, Sabbota A, Chinni SR, Cher ML.

Prostate. 2007 Jan 1;67(1):107-14.

PMID:
17075820
29.

Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.

Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, Filetti LC, Mobashery S, Cher ML, Fridman R.

Int J Cancer. 2006 Jun 1;118(11):2721-6.

30.

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML.

Prostate. 2006 Jan 1;66(1):32-48.

PMID:
16114056
31.

The transition to the metastatic phenotype of rat lymphoma cells involves up-regulation of IL-10 receptor expression and IL-10 secretion.

Rico MJ, Matar P, Gervasoni SI, Bonfil RD, Calcaterra N, Scharovsky OG.

Clin Exp Metastasis. 2005;22(2):127-35.

PMID:
16086233
32.

Potent mechanism-based inhibitors for matrix metalloproteinases.

Ikejiri M, Bernardo MM, Bonfil RD, Toth M, Chang M, Fridman R, Mobashery S.

J Biol Chem. 2005 Oct 7;280(40):33992-4002. Epub 2005 Jul 26.

33.

Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.

Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML.

Am J Pathol. 2005 Apr;166(4):1173-86.

34.

Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance.

Scharovsky OG, Binda MM, Rozados VR, Bhagat S, Cher ML, Bonfil RD.

Clin Exp Metastasis. 2004;21(2):177-83.

PMID:
15168735
35.

Matrix metalloproteinaes and bone metastasis.

Bonfil RD, Osenkowski P, Fridman R, Cher ML.

Cancer Treat Res. 2004;118:173-95. Review. No abstract available.

PMID:
15043193
36.

A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression.

Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Cher ML, Schuger L, Kim HR.

Cancer Res. 2004 Mar 1;64(5):1722-9.

37.

Elevated levels of angiostatin in effusions from patients with malignant disease.

Rotenberg RG, Rozas NS, Guerri L, Cher ML, Gamboni M, Lema N, Bonfil RD.

Oncol Rep. 2004 Feb;11(2):523-8.

PMID:
14719094
38.

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M.

Urol Oncol. 2002 Jul-Aug;7(4):159-66.

PMID:
12474532
39.

Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.

Binda MM, Matar P, González AD, Rozados VR, Gervasoni SI, Scharovsky OG, Bonfil RD.

Int J Cancer. 2002 Jul 1;100(1):14-21.

40.

Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline.

Gude RP, Binda MM, Boquete AL, Bonfil RD.

J Cancer Res Clin Oncol. 2001 Oct;127(10):625-30.

PMID:
11599799
41.

CT-2584 (Cell Therapeutics).

Bonfil RD.

Curr Opin Investig Drugs. 2001 Mar;2(3):424-7.

PMID:
11575717
42.

Immunohistochemical analysis of Ki-67, p21waf1/cip1 and apoptosis in marker lesions from patients with superficial bladder tumours treated with vinorelbine intravesical therapy in a preliminary phase I trial.

Bonfil RD, Gonzalez AD, Siguelboim D, Cuello Carrion FD, Ciocca DR, Villaronga A, Metz L, Mosso F, Fayad E, Reale M, Schmilovich AJ.

BJU Int. 2001 Sep;88(4):425-31.

43.

Differential anthracycline sensitivity in two related human colon carcinoma cell lines expressing similar levels of P-glycoprotein.

Boquete AL, Vargas Roig L, López GA, Gude R, Binda MM, González AD, Ciocca DR, Bonfil RD.

Cancer Lett. 2001 Apr 10;165(1):111-6.

PMID:
11248426
44.

Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide.

Matar P, Rozados VR, González AD, Dlugovitzky DG, Bonfil RD, Scharovsky OG.

Eur J Cancer. 2000 May;36(8):1060-6.

PMID:
10885612
45.

Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma.

Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD, Scharovsky OG.

Clin Exp Metastasis. 1999 Feb;17(1):19-25.

PMID:
10390143
46.

Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.

Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzó M, Bonfil RD, Fabra A.

Gene Ther. 1999 Jan;6(1):22-33.

47.

Studies on the mechanisms responsible for inhibition of experimental metastasis of B16-F10 murine melanoma by pentoxifylline.

Gude RP, Binda MM, Presas HL, Klein-Szanto AJ, Bonfil RD.

J Biomed Sci. 1999 Mar-Apr;6(2):133-41.

PMID:
10087444
49.

Modulation of the antimetastatic effect of a single low dose of cyclophosphamide on rat lymphoma.

Matar P, Rozados VR, Roggero EA, Bonfil RD, Scharovsky OG.

Tumour Biol. 1998;19(2):69-76.

PMID:
9486558
50.

Intravesical therapy with vinorelbine tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder.

Bonfil RD, Russo DM, Schmilovich AJ, Garcia-Palazzo IB.

J Urol. 1997 Sep;158(3 Pt 1):912-5.

PMID:
9258118

Supplemental Content

Loading ...
Support Center